Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 12/2015

01-12-2015 | Research Article

Transforming growth factor β type II receptor as a marker in diffuse large B cell lymphoma

Authors: Shudan Mao, Wenqi Yang, Limei Ai, Zhe Li, Jieping Jin

Published in: Tumor Biology | Issue 12/2015

Login to get access

Abstract

The objective of this study was to investigate the expression and significance of the transforming growth factor β type II receptor (TGFβRII) in diffuse large B cell lymphoma. All patients were enrolled at the First Affiliated Hospital of Liaoning Medical University between 2001 and 2007. The median follow-up period was 53.3 months. Of the 338 patients studied, 131 (38.76 %) had TGFβRII positive expression on immunohistochemistry. The 5 year survival rate was significantly higher in patients with TGFβRII expression than in those without TGFβRII expression (40.3 vs. 31.6 %, P = 0.041). Multivariate analysis identified TGFβRII expression as an independent predictive parameter for survival, in addition to lactate dehydrogenase, clinical stage, and histologic subtype. TGFβRII expression may be considered a new prognostic factor of diffuse large B cell lymphoma.
Literature
1.
Swerdlow SH, Campo E, Harris NL, et al., editors. World Health Organization classification of tumours of haematopoietic and lymphoid tissues (edition 4). Lyon: International Agency for Research on Cancer Press; 2008.
2.
Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol. 1998;16:2780–95.CrossRefPubMed
3.
Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–92.PubMed
4.
Jaffe ES, Harris NL, Diebold J, Muller-Hermelink HK. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report. Am J Clin Pathol. 1999;111:S8–S12.PubMed
5.
Coiffier B, Gisselbrecht C, Vose JM, et al. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d’Etudes des Lymphomes Agressifs. J Clin Oncol. 1991;9:211–9.CrossRefPubMed
6.
Hermine O, Haioun C, Lepage E, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin’s lymphoma. Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood. 1996;87:265–72.PubMed
7.
Kramer MH, Hermans J, Parker J, et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a populationbased study. J Clin Oncol. 1996;14:2131–8.CrossRefPubMed
8.
Hill ME, MacLennan KA, Cunningham DC, et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin’s lymphoma: a British National Lymphoma Investigation Study. Blood. 1996;88:1046–51.PubMed
9.
Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin’s lymphoma. Blood. 1997;90:244–51.PubMed
10.
Koduru PR, Raju K, Vadmal V, et al. Correlation between mutation in p53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin’s lymphoma. Blood. 1997;90:4078–91.PubMed
11.
Ichikawa A, Kinoshita T, Watanabe T, et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med. 1997;337:529–34.CrossRefPubMed
12.
Zhang H, Gao J, Zhao Z, Li M, Liu C. Clinical implications of SPRR1A expression in diffuse large B-cell lymphomas: a prospective, observational study. BMC Cancer. 2014;14:333.CrossRefPubMedPubMedCentral
13.
Liu C, Lu Y, Wang B-b, Zhang Y-j, Zhang R-s, Lu Y, et al. Clinical implications of stem cell gene Oct-4 expression in breast cancer. Ann Surg. 2011;253:1165–71.CrossRefPubMed
14.
Liu C, Cao X, Zhang Y, Xu H, Zhang R, Wu Y, et al. Co-expression of Oct-4 and Nestin in human breast cancers. Mol Biol Rep. 2012;39:5875–81.CrossRefPubMed
15.
Xu D, Xu H, Ren Y, Liu C, Wang X, Zhang H, et al. Cancer stem cell-related gene periostin: a novel prognostic marker for breast cancer. PLoS One. 2012;7(10):e46670.CrossRefPubMedPubMedCentral
16.
Hao Zhang, Yuan Ren, Huanming Xu, Deyan Pang, Chao Duan, Caigang Liu. The expression of stem cell protein Piwil2 and piR-932 in breast cancer. 2013 Aug 27. pii: S0960-7404(13)00066-2.
17.
Liu B, Nicolaides NC, Markowitz S, Willson JKV, Parsons RE, Jen J, et al. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat Genet. 1995;9:48.CrossRefPubMed
18.
Thibodeau SN, French AJ, Roche PC, Cunningham JM, Tester DJ, Lindor NM, et al. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res. 1996;56:4836.PubMed
19.
Umar A, Boyer JC, Thomas DC, Nguyen DC, Risinger JI, Boyd J, et al. Defective mismatch repair in extracts of colorectal and endometrial cancer cell lines exhibiting microsatellite instability. J Biol Chem. 1994;269:14367.PubMed
20.
Boyer JC, Umar A, Risinger JI, Lipford JR, Kane M, Yin S, et al. Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. Cancer Res. 1995;55:6063.PubMed
21.
Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair defective human tumor cell lines. Cancer Res. 1997;57:808.PubMed
22.
Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A. 1998;95:6870.CrossRefPubMedPubMedCentral
23.
Simpkins SB, Bocker T, Swisher EM, Mutch DG, Gersell DJ, Kovatich AJ, et al. hMLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Hum Mol Genet. 1999;8:661.CrossRefPubMed
24.
Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, et al. Inactivation of the type II TGFβ receptor in colon cancer cells with microsatellite instability. Science. 1995;268:1336.CrossRefPubMed
25.
Yamamoto H, Sawai H, Perucho M. Frameshift somatic mutations in gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res. 1997;57:4420.PubMed
26.
Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science. 1997;275:967.CrossRefPubMed
27.
Schwartz Jr S, Yamamoto H, Navarro M, Maestro M, Reventos J, Perucho M. Frameshift mutations at mononucleotide repeats in caspase-5 and other target genes in endometrial and gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res. 1999;59:2995.PubMed
28.
Stansfeld AG, Diebold J, Noel H, et al. Updated Kiel classification for lymphomas. Lancet. 1988;1:292–3.CrossRefPubMed
29.
Isufi I, Seetharam M, Zhou L, Sohal D, Opalinska J, et al. Transforming growth factor-beta signaling in normal and malignant hematopoiesis. J Interferon Cytokine Res. 2007;27:543–52.CrossRefPubMed
30.
Santibanez JF, Quintanilla M, Bernabeu C. TGF-beta/TGF-beta receptor system and its role in physiological and pathological conditions. Clin Sci (Lond). 2011;121:233–51.CrossRef
31.
Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, et al. TGF beta signals through a heteromeric protein kinase receptor complex. Cell. 1992;71:1003–14.CrossRefPubMed
32.
Derynck R, Zhang Y. Smad-dependent and Smad-independent pathways in TGF-family signalling. Nature. 2003;425:577–84.CrossRefPubMed
33.
34.
Rehmann JA, LeBien TW. Transforming growth factorbeta regulates normal human pre-Bcell differentiation. Int Immunol. 1994;6:315–22.CrossRefPubMed
35.
Kehrl JH, Thevenin C, Rieckmann P, et al. Transforming growth factor-beta suppresses human Blymphocyte Ig production by inhibiting synthesis and the switch from the membrane form to the secreted form of Ig mRNA. J Immunol. 1991;146:4016–23.PubMed
36.
Smeland EB, Blomhoff HK, Holte H, et al. Transforming growth factor type beta (TGF beta) inhibits G1 to S transition, but not activation of human Blymphocytes. Exp Cell Res. 1987;171:213–22.CrossRefPubMed
37.
Bouchard C, Fridman WH, Sautes C. Effect of TGF-beta1 on cell cycle regulatory proteins in LPS-stimulated normal mouse Blymphocytes. J Immunol. 1997;159:4155–64.PubMed
38.
Djaborkhel R, Tvrdik D, Eckschlager T, et al. Cyclin A down-regulation in TGFbeta1-arrested follicular lymphoma cells. Exp Cell Res. 2000;261:250–9.CrossRefPubMed
39.
Kehrl JH, Roberts AB, Wakefield LM, et al. Transforming growth factor beta is an important immunomodulatory protein for human Blymphocytes. J Immunol. 1986;137:3855–60.PubMed
40.
Wahl SM, Hunt DA, Wong HL, et al. Transforming growth factor is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation. J Immunol. 1988;140:3026–32.PubMed
41.
Ranges GE, Figari IS, Espevik T, et al. Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med. 1987;166:991–8.CrossRefPubMed
42.
Lotz M, Ranheim E, Kipps TJ. Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia Bcells. J Exp Med. 1994;179:999–1004.CrossRefPubMed
43.
Lebman DA, Edmiston JS. The role of TGF-beta in growth, differentiation, and maturation of Blymphocytes. Microbes Infect. 1999;1:1297–304.CrossRefPubMed
44.
Chaouchi N, Arvanitakis L, Auffredou MT, et al. Characterization of transforming growth factor-beta 1 induced apoptosis in normal human Bcells and lymphoma Bcell lines. Oncogene. 1995;11:1615–22.PubMed
Metadata
Title
Transforming growth factor β type II receptor as a marker in diffuse large B cell lymphoma
Authors
Shudan Mao
Wenqi Yang
Limei Ai
Zhe Li
Jieping Jin
Publication date
01-12-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3700-z

Other articles of this Issue 12/2015

Tumor Biology 12/2015 Go to the issue

Editorial

The association between methylenetetrahydrofolate reductase gene C677T polymorphisms and breast cancer risk in Chinese population

Research Article

Plakophilin 1-deficient cells upregulate SPOCK1: implications for prostate cancer progression

Research Article

High expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinoma

Research Article

Antitumor effects evaluation of a novel porphyrin derivative in photodynamic therapy

Research Article

Integrative functional genetic-epigenetic approach for selecting genes as urine biomarkers for bladder cancer diagnosis

Research Article

Elevated miR-483-3p expression is an early event and indicates poor prognosis in pancreatic ductal adenocarcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits